Total number of voting rights and size of share capital as of 31 July 2009 after reduction of the share capital of H. Lundbeck A/S
On 21 April 2009, the Annual General Meeting of H. Lundbeck A/S resolved to reduce the company's share capital by a nominal amount of DKK 3,848,240 by reducing the company's holding of treasury shares.
The resolution was announced in the electronic information system of the Danish Commerce and Companies Agency on 23 April 2009, and the statutory notice period has now expired with no claims received. Accordingly, the reduction of the company's share capital was registered with the Danish Commerce and Companies Agency today. Following the reduction of capital, the nominal share capital of H. Lundbeck A/S as of 31 July 2009 amounts to 980,583,170 divided into 196,116,634 shares of DKK 5 each and 196,116,634 votes. Lundbeck contacts Investors: Media: Jacob Tolstrup Mads Kronborg Director, IR & Communication Media Relations +45 36 43 30 79 +45 36 43 28 51 Palle Holm Olesen Kasper Riis Head of Investor Relations Media Relations +45 36 43 24 26 +45 36 43 28 33 Magnus Thorstholm Jensen Investor Relations Officer +45 36 43 38 16 About Lundbeck H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company highly committed to improve the quality of life for people suffering from central nervous system (CNS) disorders. For this purpose Lundbeck is engaged in the research and development, production, marketing and sale of pharmaceuticals across the world, targeted at disorders like depression and anxiety, schizophrenia, insomnia, Huntington's, Alzheimer's and Parkinson's diseases. Lundbeck was founded in 1915 by Hans Lundbeck in Copenhagen, Denmark, and employs today over 5,500 people worldwide. Lundbeck is one of the world's leading pharmaceutical companies working with CNS disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). For more information, please visit www.lundbeck.com.